Switch theme
Sign up to access all valuation multiples
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
2016
115
LTM Revenue $15.8M
LTM EBITDA n/a
-$66.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Generation Bio has a last 12-month revenue of $15.8M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Generation Bio achieved revenue of $19.9M and an EBITDA of -$74.3M.
Generation Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Generation Bio valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $5.9M | $19.9M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$133M | -$74.3M | XXX | XXX | XXX |
| EBITDA Margin | -2258% | -373% | XXX | XXX | XXX |
| Net Profit | -$137M | -$127M | XXX | XXX | XXX |
| Net Margin | -2314% | -636% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Generation Bio's stock price is $0.
Generation Bio has current market cap of $25.1M, and EV of -$66.6M.
See Generation Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$66.6M | $25.1M | XXX | XXX | XXX | XXX | $-1.73 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Generation Bio has market cap of $25.1M and EV of -$66.6M.
Generation Bio's trades at -4.2x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Generation Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Generation Bio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$66.6M | XXX | XXX | XXX |
| EV/Revenue | -3.3x | XXX | XXX | XXX |
| EV/EBITDA | 0.9x | XXX | XXX | XXX |
| P/E | -0.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGeneration Bio's NTM/LTM revenue growth is -64%
Generation Bio's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Generation Bio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Generation Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Generation Bio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 237% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -373% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -44% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -437% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 190% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 308% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 498% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Generation Bio acquired XXX companies to date.
Last acquisition by Generation Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Generation Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Generation Bio founded? | Generation Bio was founded in 2016. |
| Where is Generation Bio headquartered? | Generation Bio is headquartered in United States of America. |
| How many employees does Generation Bio have? | As of today, Generation Bio has 115 employees. |
| Who is the CEO of Generation Bio? | Generation Bio's CEO is Dr. Geoffrey McDonough, M.D.. |
| Is Generation Bio publicy listed? | Yes, Generation Bio is a public company listed on NAS. |
| What is the stock symbol of Generation Bio? | Generation Bio trades under GBIO ticker. |
| When did Generation Bio go public? | Generation Bio went public in 2020. |
| Who are competitors of Generation Bio? | Similar companies to Generation Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Generation Bio? | Generation Bio's current market cap is $25.1M |
| What is the current revenue of Generation Bio? | Generation Bio's last 12-month revenue is $15.8M. |
| What is the current EV/Revenue multiple of Generation Bio? | Current revenue multiple of Generation Bio is -4.2x. |
| What is the current revenue growth of Generation Bio? | Generation Bio revenue growth between 2023 and 2024 was 237%. |
| Is Generation Bio profitable? | Yes, Generation Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
